來源: WSJ Markets ↗
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness
|
暫時無法翻譯，請重試。
來源報導重點
Heart disease remains humanity’s top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.
在 WSJ Markets 閱讀原始報導 ↗